Zymeworks Q2 2024 net loss $69.3M; cash $395.9M; zanidatamab BLA priority review by Nov 29

Zymeworks Inc.

2024-Q2 EPS reported -$0.91 revenue$29,273,000

Net loss for H1 2024: $69.3M vs $75.5M loss in H1 2023; revenue $29.3M (down from $42.6M).
Cash, equivalents and marketable securities $395.9M as of June 30, 2024; runway into 2H 2027.
FDA granted Priority Review for zanidatamab BLA in 2L HER2+ BTC; PDUFA date Nov 29, 2024.
Discontinued zanidatamab zovodotin (ZW49) to focus on ZW171 and ZW191 Phase 1 starts in 2H 2024.
Appointed Leone Patterson as EVP, Chief Business Officer and CFO, effective Sep 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.